- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy ; volume:15 ; number:1 ; day:8 ; month:1 ; year:2024 ; pages:1-16 ; date:1.2024
Cell death & disease ; 15, Heft 1 (8.1.2024), 1-16, 1.2024
- Creator
-
Babamohamadi, Mehregan
Mohammadi, Nastaran
Faryadi, Elham
Haddadi, Maryam
Merati, Amirhossein
Ghobadinezhad, Farbod
Amirian, Roshanak
Izadi, Zhila
Hadjati, Jamshid
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-023-06391-x
- URN
-
urn:nbn:de:101:1-2024032210115739817887
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Babamohamadi, Mehregan
- Mohammadi, Nastaran
- Faryadi, Elham
- Haddadi, Maryam
- Merati, Amirhossein
- Ghobadinezhad, Farbod
- Amirian, Roshanak
- Izadi, Zhila
- Hadjati, Jamshid
- SpringerLink (Online service)
Other Objects (12)
Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage
Nanobody-based CAR-T cells for cancer immunotherapy
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
Nanobody: a promising toolkit for molecular imaging and disease therapy
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
A CTLA-4 blocking strategy based on Nanobody in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage
Nanobody-based CAR-T cells for cancer immunotherapy
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
Nanobody: a promising toolkit for molecular imaging and disease therapy
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
A CTLA-4 blocking strategy based on Nanobody in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage
Nanobody-based CAR-T cells for cancer immunotherapy
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
Nanobody: a promising toolkit for molecular imaging and disease therapy
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
A CTLA-4 blocking strategy based on Nanobody in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?